| AFF |
Forum Affimed geopend
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortIn...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerEfficacy and safety of AFM24 in combination with atezolizumab,...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed HyperlipidemiaMay 29, 2024PDF Version- Zodasiran significantly reduced triglycerides and atherogenic trigl...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed HyperlipidemiaMay 28, 2024PDF Version- Plozasiran significantly lowered triglyceride levels with commensu...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinica...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
quote:de tuinman schreef op 15 mei 2024 17:55:[...]Ik heb sinds kort Discord. Heb je tips voor me?Geen extra tips, Tuinman.Het wijst zichzelf, gewoon lezen en er het jouw...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
We zijn alvast in goed gezelschap met onze visie ;-)...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressTreatment with AFM28 innate cell engager (ICE®), ...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Artal Group S.A. Top Holdings and 13F Report (2024)www.marketbeat.com/13f-filings/artal-...Heel interessante info van Discord.Dit fonds, gesticht door de rijkste Belg Eric Wittouck...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyThe preliminary results from the phase 2 study investigating AFM24 in c...
|
Missolapola |
| ANA |
Forum Anavex Life Sciences Corp geopend
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humanswww.anavex.com/post/anavex-life-scien...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheckMANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncolo...
|
Missolapola |
| ANA |
Forum Anavex Life Sciences Corp geopend
finance.yahoo.com/news/anavex-life-sc...Minder goeie start van 2024 voor Anavex …...
|
Missolapola |
| AFF |
Forum Affimed geopend
Iedereen hier een vruchtbaar beursjaar 2024 gewenst! Voor de investeerders in deze sector kan het toch bijna niet slechter worden dan het in 2023 was.Laat ons hopen dat we dit jaar de heropstanding...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (B...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer PatientsData update from AFM...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH ...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressAcimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203. Compa...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-st...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
quote:de tuinman schreef op 28 oktober 2023 14:54:[...]Waar heb ik dit nog meer gelezen..In tien minuten zes keer een déja-vu ;-)...
|
Missolapola |
| AFF |
Forum Affimed geopend
Affimed Announces Listing Transfer to Nasdaq Capital MarketsMANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-on...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1June 27, 2023PASADENA, Calif.--(BUSINESS WIRE)--Jun. 27, 2023-- Arrowhead Pharmaceuticals, Inc. (NAS...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
ir.arrowheadpharma.com/news-releases/...Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational...
|
Missolapola |
| ANA |
Forum Anavex Life Sciences Corp geopend
June 1 (Reuters) - Anavex Life Sciences Corp AVXL.O : * ANAVEX ANNOUNCES ISSUANCE OF NEW U.S. INTELLECTUAL PROPERTY COMPOSITIONS PATENT FOR ANAVEX®2-73 (BLARCAMESINE) * ANAVEX LIFE SCIENCES CORP - PAT...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
ir.arrowheadpharma.com/news-releases/...
|
Missolapola |
| AFF |
Forum Affimed geopend
Ik blijf hier zitten (GAK van $ 0,95) en wacht op een overname/verkoop/partnering.Heb het even nagekeken en op 7/7/2021 heb ik mijn ganse portefeuille met voornamelijk biotech verkocht en het is ont...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Arrowhead Pharmaceuticals Remains A Buy For Pipeline Potential seekingalpha.com/article/4606150-arro...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Bedankt, Piddy!...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Zou er iemand een uitnodigingslink voor Discord ARWR willen plaatsen? Ik geraak er niet meer op. Alvast bedankt!...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Arrowhead delivers in the lung | Evaluatewww.evaluate.com/vantage/articles/int...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect | Arrowhead Pharmaceuticals Inc. ir.arrowheadpharm...
|
Missolapola |
| AFF |
Forum Affimed geopend
www.goingpublic.de/life-sciences/affi...
|
Missolapola |
| AFF |
Forum Affimed geopend
Truist says Fate’s reboot not a negative for Affimed 7/1/2023 - 00:00 - Reuters ** Brokerage Truist Securities says Fate Therapeutics major business reboot might be a critical point fo...
|
Missolapola |
| AFF |
Forum Affimed geopend
Eergisteren hier terug ingestapt. En ook bij AVXL.En voor de rest: veel ARWR ;-)...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Meanwhile AMG-890 - now known as Olpasiran - is being rushed into pivotal trials by Amgen after Phase 2 tests revealed a 90% or greater reduction in Lp(A) levels – a biomarker for cardiovascular disea...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
ARO-APOC-3 is designed to reduce production of Apolipoprotein C-III - a component of triglyceride rich lipoproteins (TRLs), and its being evaluated in a Phase 3 study in patients with...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
If you are therefore prepared to take Arrowheads charismatic, ambitious CEOs word for it, and continue to have faith that the TRiM platform is best in class in the RNAi field - superior, for...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Announcing fiscal 2022 third quarter results, Arrowhead revealed it had earned revenues (from its various partner deals) of $212m across the 9m to June 30, but made a net loss of $90.5, with total ope...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Vervolg artikel:Arrowhead received a $175m upfront payment, JNJ made a $75m equity investment, and there are up to $1.6bn of milestone payments written into the agreement, plus tiered royalties on...
|
Missolapola |
| ARR |
Forum Arrowhead Research geopend
Arrowhead: Emerging From The Data Desert With A Flood Of Opportunities (NASDAQ:ARWR) | Seeking Alphaseekingalpha.com/article/4540501-arro...
|
Missolapola |
| PRO |
ProQR Therapeutics 2022
Wat een drama, mijn medeleven met iedereen die er tot vandaag nog inzit/inzat...
|
Missolapola |
| AFF |
Forum Affimed geopend
[quote alias=Tom3 id=14014131 date=202202091710][...]Achteraf een goede timing lijkt me. Heb je een hot line met Blackrock en consorten? Die hebben volgens mij geholpen bij het laag houden van d...
|
Missolapola |
| AFF |
Forum Affimed geopend
Ik doe opnieuw mee hier, heb mij terug een pakket Affimed aangeschaft...
|
Missolapola |
| GAL |
Galapagos februari 2022
Bedankt voor je openingspost, Galajurk!Het artikel van vandaag uit De Tijd heb ik in het januaridraadje geplaatst en ik zie dat Voda het hier al had gepost.Iedereen veel succes gewenst in deze woe...
|
Missolapola |
| GAL |
Galapagos januari 2022
Uit De Tijd van vandaag:De Californische biotechinvesteerder Oleg Nodelman heeft zijn belang in de biotechgroep opgedreven tot meer dan 5 procent. Een motie van vertrouwen in nieuwe CEO Paul Stoff...
|
Missolapola |
| GAL |
Galapagos januari 2022
quote:Endless schreef op 27 januari 2022 22:02:[...]Hoi lang niks van je gehoord zit je er weer in. Je was iedergeval toen boven 200 uitgestapt, achteraf een slimme move. Hoi Endle...
|
Missolapola |
| GAL |
Galapagos januari 2022
[quote alias=Galajurk id=13984074 date=202201271800][...]Ook ik koester die tijd , mooie herinneringen.Met een nieuwe topman het besef dat er definitief een einde aan een tijdperk is gekomen.
...
|
Missolapola |
| GAL |
Bericht van CEO aan Forum
[quote alias=beagle06 id=13981466 date=202201262215]Beste forum leden, zojuist hebben we aangekondigd dat Paul Stoffels de nieuwe CEO gaat worden. Ik ben enorm trots en blij dat Paul het stokje ove...
|
Missolapola |
| PRO |
ProQR Therapeutics 2021
www.proqr.com/press-releases/proqr-an...
|
Missolapola |
| GAL |
Galapagos september 2021
....
|
Missolapola |